ROIV News and Press, Roivant Sciences Ltd. From 07/19/23

2023-07-19 17:50:15 ET Summary Immunovant, Inc. received additional validation with anti-FcRn achieved as competitor argenx achieves primary endpoint in phase 2 study using VYVGART for the treatment of patients with CIDP. Immunovant expects to release results from its phase 2b stu...

2023-07-17 13:26:32 ET Shares of Immunovant ( NASDAQ: IMVT ) jumped 14% midday Monday amid the release of positive data for Argenx's ( ARGX ) drug Vyvgart Hytrulo, which is in the same drug class as Immunovant's drug candidate IMVT-1402. Argenx reported earlier Monday that a...

2023-07-13 19:22:04 ET Roivant Sciences ( NASDAQ: ROIV ) is close to selling its its ulcerative colitis drug candidate RVT-3101 to Roche ( OTCQX:RHHBY ) through deal that could be worth more than $7B, according to the Wall Street Journal. Roivant has been developing the drug...

BASEL, Switzerland, LONDON, and NEW YORK, July 11, 2023 (GLOBE NEWSWIRE) -- Fast Company today announced its fifth annual Best Workplaces for Innovators list, honoring organizations and businesses that demonstrate an inspiring commitment to encourage and develop innovation at all levels. ...

2023-07-10 08:48:44 ET Summary Roivant Sciences' ulcerative colitis therapy, RVT-3101, shows promising results in Phase 2b trial, attracting interest from major pharmaceutical companies. The company ended the fiscal year with a cash position of approximately $1.7 billion, with los...

2023-07-06 14:55:08 ET Shares of U.K.-based biotech Roivant Sciences ( NASDAQ: ROIV ) reached a session high on Thursday triggering a trading halt after Bloomberg reported that the company has attracted biopharma interest in $7B bowel drug. Accordig to the report, large bi...

2023-07-02 07:18:39 ET Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . For further details see: Wall Street Breakfast: The Week Ahead

2023-06-28 15:47:58 ET Shares of Roivant Sciences (NASDAQ: ROIV) were up more than 11% by 3 p.m. ET on Wednesday after the pharmaceutical company that specializes in smaller portfolio companies, called vants, released fourth-quarter and 2023 fiscal-year earnings. The stock is up...

RVT-3101 demonstrated improved efficacy results from the induction to chronic period in the TUSCANY-2 Phase 2b study in ulcerative colitis and was well tolerated with a favorable safety profile across all doses A Phase 2 study of RVT-3101 in Crohn’s disease has been initiated with to...

2023-06-28 07:24:17 ET Roivant Sciences press release ( NASDAQ: ROIV ): Q4 GAAP EPS of -$0.20 beats by $0.18 . Revenue of $27.38M (+197.0% Y/Y) beats by $9.18M . For further details see: Roivant Sciences GAAP EPS of -$0.20 beats by $0.18, revenue of $27.3...